Earlier in January 2026, Viking Therapeutics reported that its obesity drug candidate VK2735 achieved 14.7% weight loss from baseline over 13 weeks in a Phase 2 trial, meeting primary and secondary ...

Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation ...

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent ...